Direct-to-Consumer Genetic Testing vs. Clinical Genetic Testing: What's the Difference?

By Amanda Shrewsbury, MS, CGC

Genetic testing is more accessible than it''s ever been. You can order a kit online, swab your cheek at home, and get results in a few weeks. Companies like 23andMe, Ancestry, and a growing number of nutrigenomic testing providers are making DNA analysis feel as routine as ordering a supplement.

But here''s the thing: not all genetic tests are built for the same purpose, and not all genetic tests are held to the same standards. A test that tells you interesting things about your ancestry or caffeine metabolism is a fundamentally different tool than one designed to determine whether you carry a hereditary cancer variant that changes how you''re screened and managed for the rest of your life.

If you''ve already taken a direct-to-consumer (DTC) test and are wondering what your results mean for your cancer risk, or if you''re trying to figure out which type of testing is right for you, this guide will walk you through the distinctions that matter.

What Is Direct-to-Consumer Genetic Testing?

DTC genetic testing refers to tests you can order yourself without a physician''s referral or a genetic counselor''s involvement. You typically purchase a kit online, provide a saliva or cheek swab sample at home, mail it to the company, and receive results through an app or website.

The most well-known DTC company is 23andMe, which offers ancestry reports, trait information (like whether you''re likely to have curly hair or dislike cilantro), and some health-related genetic reports. Other companies focus specifically on ancestry (Ancestry.com), carrier screening, or wellness-related insights.

DTC tests typically use a technology called SNP genotyping (pronounced "snip"). This method looks at specific, pre-selected locations in your DNA where common variations are known to exist. Think of it as checking a few highlighted words on a page rather than reading the entire book. It''s fast and affordable, but it only tells you about the specific spots the test was designed to look at.

What Is Nutrigenomic Testing?

A newer category of genetic testing that''s gaining popularity focuses on nutrigenomics, the study of how your genes interact with nutrition, metabolism, and lifestyle factors. Companies like 3x4 Genetics analyze genetic variants related to how your body handles inflammation, detoxification, hormone metabolism, nutrient absorption, and athletic performance.

Nutrigenomic testing can offer genuinely interesting and sometimes useful information. If you''re working with a nutritionist, functional medicine practitioner, or health coach, these results can help personalize dietary and supplement recommendations based on your individual genetic profile. Many people find value in understanding, for example, why they respond differently to caffeine, how their body metabolizes certain fats, or whether they have variants that affect vitamin D utilization.

But it''s important to understand what nutrigenomic testing is and isn''t. These tests analyze common genetic variants (SNPs) that influence wellness and metabolic pathways. They are not designed to identify rare, high-penetrance pathogenic variants in cancer predisposition genes like BRCA1/BRCA2 or the mismatch repair genes associated with Lynch syndrome. The genes being tested, the technology being used, and the clinical questions being answered are fundamentally different.

A nutrigenomic test that says you have a variant affecting methylation or detoxification is not telling you whether you carry a hereditary cancer syndrome. And a clinical cancer genetic test is not designed to tell you how you metabolize carbohydrates. They live in different lanes.

What Is Clinical Genetic Testing?

Clinical genetic testing is ordered by a healthcare provider (often a genetic counselor), processed in a laboratory that meets rigorous quality standards, and designed to answer specific medical questions. For hereditary cancer risk, this typically means a multigene panel test that sequences entire genes known to be associated with cancer predisposition.

Here''s how clinical testing differs from DTC and nutrigenomic testing at the technical level:

Comprehensive gene sequencing vs. spot-checking. Clinical tests use next-generation sequencing (NGS) to read through the full coding regions of cancer predisposition genes. This means they can detect the full range of pathogenic variants, including rare ones specific to your family. DTC tests using SNP genotyping only check for pre-selected variants and miss the vast majority.

Laboratory standards. Clinical genetic testing laboratories are required to be CLIA-certified (Clinical Laboratory Improvement Amendments) and are typically CAP-accredited (College of American Pathologists). These certifications mean the lab has undergone rigorous quality checks, regular proficiency testing, and external validation. DTC and nutrigenomic labs may or may not hold these certifications, and they are not universally required to do so.

Confirmation of results. Clinical labs typically confirm pathogenic findings using a second, independent method (often Sanger sequencing) before issuing a report. This double-check significantly reduces the risk of false positives. DTC tests generally do not perform this confirmation step.

Expert interpretation. Clinical genetic test results come with interpretation by board-certified laboratory geneticists and are designed to be reviewed with a genetic counselor or other qualified provider who can explain the findings in the context of your personal and family history. DTC results are typically delivered through an app with limited or no access to a genetics professional.

Why Does This Distinction Matter for Cancer Risk?

The risk of conflating different types of genetic testing is real, and it cuts in both directions.

False reassurance is the bigger concern. If you''ve taken a DTC test that came back "negative" for BRCA variants, it may feel like you''ve been cleared. But the 23andMe BRCA report, for example, currently tests for 44 out of more than 4,000 known pathogenic variants in the BRCA1 and BRCA2 genes. For people of Ashkenazi Jewish descent, the test covers a meaningful proportion of common variants. But for the general population, it captures only about 30–40% of BRCA carriers of African American, European, and Hispanic/Latino descent, and as few as 5–25% for people of East Asian descent (23andMe, 2023). A negative result on this test does not mean you don''t carry a BRCA variant. It means you don''t carry one of the specific variants the test looked for.

The same principle applies to nutrigenomic tests. A nutrigenomic panel may include genes that overlap with cancer pathways (such as MTHFR or COMT), but it is not evaluating these genes in the context of hereditary cancer risk and is not using the methodology or laboratory standards required for clinical cancer risk assessment.

False alarm is the other side. DTC tests can also produce results that are confusing or anxiety-provoking without the context a genetic counselor provides. A variant flagged as "increased risk" on a DTC report may be a common, low-impact variant that doesn''t change medical management, but a person reading the report at home may not know that.

What Should You Do If You''ve Already Taken a DTC or Nutrigenomic Test?

First, don''t dismiss what you''ve learned. If your DTC test identified a BRCA or other cancer-related variant, that finding should be taken seriously, confirmed through clinical testing, and reviewed with a genetic counselor. A positive result on a DTC test is likely real, even if it needs confirmation.

If your DTC test was negative, understand that a negative result is not the same as a clean bill of health when the test only looked at a fraction of possible variants. If you have a personal or family history that suggests hereditary cancer risk (multiple relatives with cancer, early-onset cancers, specific cancer patterns), clinical genetic testing may still be warranted regardless of your DTC result.

If you''ve taken a nutrigenomic test and found it valuable for understanding your nutrition and metabolism, that''s great. Use those insights for what they''re designed for. But don''t assume they''ve assessed your hereditary cancer risk, because they haven''t.

And if you''re not sure which type of testing you''ve had, or what your results mean, that''s one of the most common and most important reasons to talk to a genetic counselor. It''s a conversation we have regularly at ClearPath Genetics, and there are no wrong questions. (Wondering what that appointment looks like? See: What Actually Happens During a Genetic Counseling Appointment.)

How Does ClearPath Genetics Approach Testing?

At ClearPath Genetics, we use clinical-grade multigene panel testing processed in CLIA-certified, CAP-accredited laboratories. Our panels are designed to comprehensively sequence the genes most relevant to hereditary cancer risk, giving you a clear, clinically actionable answer rather than a partial picture.

Every test comes with a pre-test genetic counseling session where we review your personal and family history, explain what the testing can and can''t tell you, and make sure you''re prepared for any result. And every result, whether positive, negative, or uncertain (including VUS), is reviewed in a dedicated results appointment with your genetic counselor.

This is the standard of care in genetics, and it''s what separates clinical testing from any test you can order on your own.

Have a question? Reach out anytime:

References

  • Genetic Support Foundation. (2024). The value of knowledge and the cost of false reassurance: Understanding the updates to 23andMe''s BRCA genetic testing.
  • National Human Genome Research Institute. (2024). Direct-to-consumer genetic testing FAQ for healthcare professionals. https://www.genome.gov

This blog post is for educational purposes only and does not constitute medical advice. Visit clearpathgenetics.com to learn more. © 2026 ClearPath Genetics, LLC. All rights reserved.